Literature DB >> 1595114

Stroke after pituitary irradiation.

J Bowen1, C A Paulsen.   

Abstract

BACKGROUND AND
PURPOSE: Cranial irradiation may lead to accelerated atherosclerosis over several years. Stroke has been described after cranial irradiation administered for a number of conditions. However, pituitary irradiation has only rarely been associated with stroke. CASE DESCRIPTIONS: Two patients, 39 and 46 years of age, suffered strokes 13 and 20 years, respectively, after irradiation for pituitary tumors. Strokes were in the territories of small perforating arteries, but large vessels such as the carotid siphon and anterior cerebral arteries were also abnormal. Other risk factors for stroke were absent.
CONCLUSIONS: It is suggested that pituitary irradiation increases the risk of subsequent stroke due to the known effects of ionizing radiation on vascular walls.

Entities:  

Mesh:

Year:  1992        PMID: 1595114     DOI: 10.1161/01.str.23.6.908

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  9 in total

1.  Percutaneous transluminal angioplasty in a patient with internal carotid artery stenosis following gamma knife radiosurgery for recurrent pituitary adenoma.

Authors:  Hidemichi Ito; Hidetaka Onodera; Taigen Sase; Masashi Uchida; Hiroyuki Morishima; Kotaro Oshio; Takashi Shuto; Yuichiro Tanaka
Journal:  Surg Neurol Int       Date:  2015-05-28

Review 2.  Intracranial metastatic disease rarely involves the pituitary: retrospective analysis of 935 metastases in 155 patients and review of the literature.

Authors:  James C Marsh; Shalini Garg; Julie A Wendt; Benjamin T Gielda; Julius V Turian; Arnold M Herskovic
Journal:  Pituitary       Date:  2010-09       Impact factor: 4.107

3.  Moyamoya syndrome: post cranial irradiation of pineal gland tumor.

Authors:  P Chiewvit; V Janyavanich; N Soonthonpong; A Churoj; O Chawalparit; S Suthipongchai
Journal:  Interv Neuroradiol       Date:  2001-07-15       Impact factor: 1.610

4.  Middle cerebral artery occlusion 25 years after cranial radiation therapy in acromegaly: a case report.

Authors:  P Maffei; I Albano; C Martini; M Barban; R Manara; G Meneghetti; N Sicolo
Journal:  J Thromb Thrombolysis       Date:  2009-01-06       Impact factor: 2.300

5.  Cerebral vasoreactivity, a surrogate marker of cerebrovascular disease, is not impaired in subjects with lifetime, untreated, congenital isolated GH deficiency.

Authors:  Cindi G Marinho; Hyder A Melo; Roberto Salvatori; Marco A P Nunes; Carla R P Oliveira; Viviane C Campos; Cynthia S Barros-Oliveira; Alécia A Oliveira-Santos; Nelmo V Menezes; Hertz T Santos-Júnior; Elenilde G Santos; Manuela A Melo; Joselina L M Oliveira; Enaldo V Melo; Manuel H Aguiar-Oliveira
Journal:  Endocrine       Date:  2020-07-12       Impact factor: 3.633

6.  Cerebral infarction after fractionated stereotactic radiation therapy of benign anterior skull base tumors.

Authors:  Arnar Astradsson; Per Munck Af Rosenschöld; Lars Poulsgaard; Lars Ohlhues; Svend Aage Engelholm; Ulla Feldt-Rasmussen; Reginald Marsh; Henrik Roed; Marianne Juhler
Journal:  Clin Transl Radiat Oncol       Date:  2019-02-07

7.  Toxicity Profiles of Fractionated Radiotherapy, Contemporary Stereotactic Radiosurgery, and Transsphenoidal Surgery in Nonfunctioning Pituitary Macroadenomas.

Authors:  Chia-Lun Chang; Kevin Sheng-Po Yuan; Alexander T H Wu; Szu-Yuan Wu
Journal:  Cancers (Basel)       Date:  2019-10-26       Impact factor: 6.639

8.  Cerebral Infarction in Childhood-Onset Craniopharyngioma Patients: Results of KRANIOPHARYNGEOM 2007.

Authors:  Svenja Boekhoff; Brigitte Bison; Daniela Genzel; Maria Eveslage; Anna Otte; Carsten Friedrich; Jörg Flitsch; Hermann L Müller
Journal:  Front Oncol       Date:  2021-07-14       Impact factor: 6.244

9.  Long-term safety of gamma knife radiosurgery (SRS) for acromegaly.

Authors:  Hugh P Sims-Williams; Kaveesha Rajapaksa; John Yianni; Lee Walton; Saurabh Sinha; Matthias Radatz; Esther Herbert; Mike Bradburn; John Newell-Price
Journal:  Pituitary       Date:  2021-05-26       Impact factor: 4.107

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.